HNSA — Hansa Biopharma AB Cashflow Statement
0.000.00%
Last trade - 00:00
- SEK1.53bn
- SEK1.66bn
- SEK134.09m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -360 | -423 | -548 | -611 | -832 |
Depreciation | |||||
Non-Cash Items | 7.15 | 43.8 | 56.4 | 71.4 | 18 |
Purchased R&D | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 10.3 | 81.1 | 2.12 | 25 | 38.3 |
Change in Accounts Receivable | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -335 | -290 | -481 | -503 | -756 |
Capital Expenditures | -3.43 | -0.294 | -2.4 | -3.33 | -0.284 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 89.2 | 183 | 0 | 233 | 0 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | 85.8 | 183 | -2.4 | 229 | -0.284 |
Financing Cash Flow Items | -7.65 | -0.001 | — | — | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -8.88 | 1,066 | -4.86 | 1,118 | -7.54 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -258 | 958 | -488 | 845 | -764 |